Status:
TERMINATED
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Cervical Intraepithelial Neoplasia
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Relationship between HPV infection and cervical cancer is well established. Among the HPV types identified to date, 15 are classified as high risk HPV (HR-HPV). Detection of HR-HPV has been proposed t...
Detailed Description
A prospective detection and quantification of HR-HPV in patients with proven CIN1 will be performed. Relationship between HR-HPV initial viral load and the CIN1 persistence will be evaluated.
Eligibility Criteria
Inclusion
- The women whose last one FCV of screening put in evidence a LIEBG of the neck of the womb having been confirmed by the colposcopie.
- The inclusive patients will be of more than 18 years old. All the patients will be profitable of a regime of Social Security.
Exclusion
- The patients whose result of the colposcopie is clashing with that of the FCV of initial screening (normal collar, LIEHG or the other one).
- The patients having an antecedent of DREGS of the neck of the womb, that this one was or not handled
- The patients having had a hysterectomy.
- The patients incapable to receive the information enlightened on the progress and the objectives of the study
- The patients not having signed enlightened assent
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00682552
Start Date
May 1 2008
End Date
February 1 2013
Last Update
August 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Nord- Service de gynécologie-obstétrique
Marseille, France, 13015